SOUTH SAN FRANCISCO, Calif., Feb. 7, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) today announced the completion of its initial public offering of 8,750,000 shares of common stock at $8.00 per share. Gross proceeds from the offering were $70 million, and net proceeds were approximately $62 million, after deducting the underwriting discounts and commissions and the estimated offering expenses payable by the company. Leerink Swann LLC acted as sole book-running manager for the offering. William Blair & Company, L.L.C. acted as the lead manager and Needham & Company LLC acted as co-manager for the offering.
A registration statement relating to these securities was declared effective by the SEC on January 31, 2013. The offering was made only by means of a prospectus, copies of which may be obtained by contacting Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by calling (800) 808-7525.
This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About KaloBios Pharmaceuticals
KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs) designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases.
SOURCE KaloBios Pharmaceuticals, Inc.